Indegene Ltd Share Price – NSE  / BSE

Healthcare, Small Cap

Net profit of Indegene rose 11.34% to Rs 102.10 crore in the quarter ended September 2025 as against Rs 91.70 crore during the previous quarter ended September 2024. Sales rose 17.09% to Rs 804.20 crore in the quarter ended September 2025 as against Rs 686.80 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Indegene will hold a meeting of the Board of Directors of the Company on 30 October 2025.

Powered by Capital Market - Live News

Indegene announced the expansion of its Consulting Practice, combining its proven strategy and transformation expertise to help life sciences organizations navigate complex, large-scale transformations across the value chain.

Life sciences companies operate in a dynamic business environment, amidst rapid technology-driven disruption. They are seeking consulting partners who not only advise on strategy but also work alongside them to implement solutions and deliver measurable outcomes. Indegene's integrated consulting practice addresses this exact need, offering clients both strategic insight and hands-on transformation implementation support.

In this context, Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability. This is another key step in the company's journey to meet the evolving needs of the life sciences industry.

Indegene has named Gobin Chandra as Head of the Integrated Consulting Practice to lead its next phase of growth. Gobin currently leads Indegene's Europe region and oversees key client relationships. He brings deep transformation advisory experience from Bain & Company and will shape the consulting charter across strategy and transformation services.

Indegene has steadily expanded its consulting capabilities over the past decade. The acquisition of DT Consulting in 2020 strengthened the company's strategy consulting expertise across customer experience and digital transformation.

In parallel, Indegene has organically built transformation consulting capabilities over the last few years. To scale this further, Indegene has acquired WARN & Co., a UK-based transformation consulting firm, enhancing its ability to drive large-scale business transformations. WARN & Co. brings deep expertise in helping global organizations design and transition to new operating models, systems, and ways of working.

Powered by Capital Market - Live News

Indegene announced the strategic acquisition of BioPharm, a Pennsylvania-based specialized marketing services agency and part of Omnicom Health Group. This acquisition by ILSL Inc., a subsidiary of Indegene, strengthens Indegene's commercialization portfolio with AdTech, combining AI and digital advertising, enabling pharma companies to drive more precise, scalable, and measurable outcomes. Further, this solidifies Indegene's position as a true category leader in data-driven Omnichannel and Media Space.

Founded in 2005, BioPharm's clients include 17 of the world's top 25 biopharma organizations. The agency brings deep expertise in omnichannel strategy, end-to-end media journey - spanning strategy, planning and operations, and data-driven campaign execution -blending analytics, automation, and targeted engagement to deliver turnkey precision marketing solutions.

Powered by Capital Market - Live News